Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, this approval and the use of ketamine generally to treat depression has met some criticism concerning the adverse effects associated with (S)-ketamine treatment, especially the dissociative properties, as well as the potential for abuse that limit patients’ treatments to specialized clinics or hospital settings”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Turner, 2019
In the citing paper
“The definition used to define TRD (i.e. a depressive episode with inadequate response to at least two trials of antidepressants—even two antidepressants of the same class (e.g. two SSRIs) [7] represents a very low stage of “resistance” and may be not relevant to day-to-day clinical practice.”
In the citing paper
“Additionally, the 3-point difference on the MARDS identified in our study corresponds with the efficacy range observed for many antidepressants and clinical significance of esketamine for TRD was previously contested, as the standardized mean difference from the three initiation pivotal trials was similar to that of other previously approved drugs for this condition [7].”
Citations
Cites
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904
Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz039 · Cited by 606
Spielmans, G. I., Berman, M. I., Linardatos, E., Rosenlicht, N. Z., Perry, A., & Tsai, A. C. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001403 · Cited by 275
Speed, Safety, and Industry Funding — From PDUFA I to PDUFA VI
Darrow, J. J., Avorn, J., & Kesselheim, A. S. (2017) · New England Journal of Medicine · doi:10.1056/nejmhle1710706 · Cited by 47
Cited by
Marx, W., Penninx, B. W. J. H., Solmi, M., Furukawa, T. A., Firth, J., Carvalho, A. F., & Berk, M. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00454-1 · Cited by 768
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731
“However, itwas subsequently noted that oneof theparticipating sites had a 100%relapse rate in theplacebo arm, which accounted for a significant overall effect in the positive relapse prevention study result (61).”
Major Depressive Disorder: Advances in Neuroscience Research and Translational Applications
Li, Z., Ruan, M., Chen, J., & Fang, Y. (2021) · Neuroscience Bulletin · doi:10.1007/s12264-021-00638-3 · Cited by 326
Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability
Bonaventura, J., Lam, S., Carlton, M., Boehm, M. A., Gomez, J. L., Solís, O., Sánchez-Soto, M., Morris, P. J., Fredriksson, I., Thomas, C. J., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01093-2 · Cited by 271
“However, this approval was not without controversy as (S)-ketamine’s efficacy and abuse liability are a concern [15, 16].”
BackgroundMolecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor
Wei, Y., Chang, L., & Hashimoto, K. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01121-1 · Cited by 248
Metadata
- Authors
- Turner, E. H.
- Affiliations
- Oregon Health & Science University (US)
- Corresponding author
- Turner, Erick H
- ORCID
- Turner, Erick H
- Venue
- The Lancet Psychiatry
- Publisher
- Elsevier BV
- Published
- 2019-12
- Volume
- 6
- Issue
- 12
- Pages
- 977-979
- ISSN
- 2215-0366 (ISSN-L)
- OpenAlex
- W2982569821
- Cited by
- 156
- References
- 4
- Citations by year
- 2026: 12 · 2025: 15 · 2024: 28 · 2023: 22 · 2022: 26 · 2021: 22 · 2020: 30 · 2019: 1
- FWCI
- 12.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet Psychiatry (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Keywords
- esketamine, treatment-resistant depression, FDA drug approval, antidepressant efficacy, antidepressant safety, NMDA receptor antagonists, ketamine, brexanolone, postpartum depression, risk-benefit assessment, breakthrough therapy designation, mental health services funding, mental health professionals
- MeSH terms
- Clinical Trials as Topic, Humans, Ketamine, United States, United States Food and Drug Administration, Treatment Outcome, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval. https://app.cochat.ai/papers/10.1016/s2215-0366(19)30394-3
- The paper
- Turner, E. H. (2019). Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval. The Lancet Psychiatry. https://doi.org/10.1016/s2215-0366(19)30394-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.